Tenax Therapeutics IncNASDAQ:TENX
- LAST PRICE5.3600
- TODAY'S CHANGE (%)0.0300 (0.5629%)
- Bid / Lots5.2000/ 2
- Ask / Lots5.3300/ 5
- Open / Previous Close5.2500 / 5.3300
- Day Range
- 52 Week Range
- Volume116,485
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TENX |
|---|---|---|
| 09:32 ET | 739 | 5.16 |
| 09:39 ET | 200 | 5.24 |
| 09:44 ET | 615 | 5.28 |
| 09:50 ET | 12960 | 5.26 |
| 09:57 ET | 100 | 5.2239 |
| 10:18 ET | 1140 | 5.2662 |
| 10:45 ET | 1700 | 5.29 |
| 10:47 ET | 100 | 5.305 |
| 10:49 ET | 300 | 5.31 |
| 10:54 ET | 200 | 5.3017 |
| 11:02 ET | 130 | 5.3 |
| 11:07 ET | 100 | 5.3227 |
| 11:09 ET | 1994 | 5.32 |
| 11:25 ET | 1100 | 5.31 |
| 11:27 ET | 125 | 5.29 |
| 11:57 ET | 230 | 5.29 |
| 11:59 ET | 3685 | 5.27 |
| 12:06 ET | 100 | 5.285 |
| 12:10 ET | 2350 | 5.3 |
| 12:12 ET | 4772 | 5.32 |
| 12:28 ET | 3534 | 5.33 |
| 12:30 ET | 1950 | 5.34 |
| 12:33 ET | 400 | 5.34 |
| 12:35 ET | 100 | 5.33 |
| 12:37 ET | 568 | 5.35 |
| 12:39 ET | 56271 | 5.3206 |
| 12:42 ET | 3941 | 5.36 |
| 12:53 ET | 10280 | 5.33 |
| 12:57 ET | 600 | 5.36 |
Nov 13, 2024
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones*DJ Tenax Therapeutics 3Q Loss/Shr 19c >TENX, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tenax Therapeutics Inc | 18.2M | -0.3x | --- |
BullFrog AI Holdings, Inc. | 18.6M | -2.5x | --- |
Neurosense Therapeutics Ltd | 19.3M | -2.2x | --- |
Acurx Pharmaceuticals Inc | 19.3M | -1.2x | --- |
Eom Pharmaceutical Holdings Inc | 16.9M | -3.9x | --- |
Finch Therapeutics Group Inc | 19.0M | -1.4x | --- |
Company Information
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Contact Information
- Headquarters
- 101 GLEN LENNOX DRIVE, SUITE 300CHAPEL HILL, NC, United States 27517
- Phone
- 919-855-2100
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Gerald Proehl
- President, Chief Executive Officer, Director
- Christopher Giordano
- Interim Chief Financial Officer
- Lawrence Hoffman
- Chief Medical Officer, Director
- Stuart Rich
- Independent Director
- June Almenoff
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.21 |
EPS | $-15.92 |
Book Value | $27.15 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
